Although, as we mentioned above, most of the data on MRGPRX2 comes from in vitro studies, there are also ongoing clinical trials using agonist of this receptor in chronic spontaneous urticaria and atopic dermatitis (12). Here, MRGPRX2 is linked to atopic eczema.